

**Reference Number:** FOI202223/545  
**From:** Other  
**Date:** 20 January 2023  
**Subject:** Skin Cancer Pathway Management

- Q1 What are your current skin cancer patient clinical pathway guidelines e.g., from initial patient symptoms in a GP setting to specialist referral as well as treatment and follow-up procedures and protocol. Attached are two outdated CCG (Clinical Commissioning Group) pathway guidelines for reference.
- A1 [Please see attached for our current skin cancer pathway guidelines: skin\\_cancer\\_pathway\\_for\\_children\\_FINAL\\_07\\_01\\_2021\\_v1.1](#)
- Q2 Does your skin cancer pathway include remote patient-clinic interactions (as opposed to face-to-face interactions), Yes or No
- a. if yes, elaborate what they are and what stage in the pathway they're used e.g., teledermatology (the use of digital photography to assess patient lesions) at the GP stage.
- A2 Yes.
- a. [We use remote consultations via phone and photo if we cannot see people within two weeks in a face to face clinic.](#)
- Q3 What were your latest skin cancer pathway guidelines in 2019/2020 prior to the COVID-19 pandemic (announced as a pandemic by WHO on 11 March 2020).
- A3 [The pathway guidance was the same pre and post pandemic. There was no changes for our Trust.](#)

# Pathway for Paediatric Skin Cancer Patients

